An empty clinical treatment room with a reclining chair, two support seats and a narrow prism of colored light crossing the floor.

The Drug Is Only Half the Policy: Lobbying the Rules for Psychedelic Medicine

Leave a Comment / Health Policy, lobbying, public affairs /

The FDA’s September 2026 hearing on psychedelic medicine highlights the complexity of lobbying for these treatments. Approval involves more than just efficacy; it requires a comprehensive approach addressing care models, supervision, professional training, funding, and regulatory controls. Successful advocacy must navigate these intertwined factors for effective public health outcomes.

The Drug Is Only Half the Policy: Lobbying the Rules for Psychedelic Medicine Read More »